Prescription medicine
Metformin
Metformin is a first-line diabetes medicine whose longevity reputation rests heavily on observational comparisons and mechanistic arguments. The definitive test — the TAME trial in people without diabetes — has been designed but has not reported. Meanwhile, even its cardiovascular benefit within diabetes is less settled than its reputation suggests.
Quick verdict
A proven diabetes medicine; an unproven longevity drug. Randomised evidence for benefits beyond diabetes does not yet exist, and meta-analysis of trials within diabetes found the cardiovascular case weaker than commonly assumed.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Reduces cardiovascular disease in type 2 diabetes | Disease outcome | Insufficient |
| Extends lifespan in people without diabetes | Lifespan | Insufficient |
Reduces cardiovascular disease in type 2 diabetes
Insufficient evidenceOutcome measured: Disease outcome — A diagnosed condition or clinical event was measured.
A meta-analysis of randomised trials found the evidence for metformin reducing cardiovascular events in type 2 diabetes to be inconclusive — surprising given how confidently this benefit is often described.
Why this grade — the appraisal in full
Too little credible research exists to judge the claim either way.
- Strongest study design. Meta-analysis of RCTs.
- Human research volume. 1 human study, 0 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
Limitations. The underlying trials are older and heterogeneous; absence of confirmed benefit is not proof of no benefit. Metformin remains first-line for glycaemic control on other grounds.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Impact of metformin on cardiovascular disease: a meta-analysis of randomised tri…Diabetologia · 2017 · PMID 28770324 | Meta-analysis of RCTsHuman | Size not recordedParticipants with a diagnosed condition | Direction not yet appraisedMeta-analysis of randomised trials in type 2 diabetes; cardiovascular effect judged inconclusive. |
Extends lifespan in people without diabetes
Insufficient evidenceOutcome measured: Lifespan — Death from any cause was measured.
No randomised trial has tested metformin for longevity in people without diabetes. The famous observational comparison suggesting treated diabetics outlived non-diabetics has known methodological problems, and the TAME trial designed to answer this question has not reported.
Why this grade — the appraisal in full
Too little credible research exists to judge the claim either way.
- Available research. No usable studies are linked to this claim.
Limitations. Observational comparisons of medicine users versus non-users are highly prone to bias; this claim is currently untested rather than supported.
Human evidence
1 study in people.
- [1]Meta-analysis of RCTs
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
No preclinical study is currently linked on this page.
Before anything else
Safety and interactions
Generally well tolerated in diabetes care; gastrointestinal effects are common, B12 deficiency can develop with long use, and it must be used cautiously with significant kidney impairment. Prescription-only.
The ledger
Grade history
No grade on this page has changed since tracking began. When one moves — a new trial, a retraction, a corrected appraisal — the change is detected automatically and recorded on the public ledger.
Falsifiability
What would change our view
Results from TAME or an equivalent randomised trial in people without diabetes, with ageing-related clinical endpoints.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes Griffin SJ, Leaver JK, Irving GJ. Diabetologia. 2017. PMID 28770324 · doi:10.1007/s00125-017-4337-9